The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2023 | The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the approval of glofitamab by the FDA for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Dr Collins highlights the safety benefits of glofitamab, particularly that it is not myelosuppressive, making it ideal for patients who have been previously treated with CAR-T therapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
